retatrutide triple agonist gip glp-1 glucagon receptor New obesity drugs are coming, including the 'triple agonist' (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and In a trial, Retatrutide caused loss of ~25% of Flavor:GLP-1 Craving Control Set Joint & Muscle Orforglipron Mechanism of Action:

retatrutide triple agonist gip glp-1 glucagon receptor New obesity drugs are coming, including the 'triple agonist' (expected for approval in 2027), which activates 3 receptors: GLP1, GIP, and In a trial, Retatrutide caused loss of ~25% of Flavor:GLP-1 Craving Control Set Joint & Muscle Orforglipron Mechanism of Action:

Orforglipron Mechanism of Action: How It Works

Its primary licensed indication — in the United States, under the brand name Egrifta — is the reduction of excess visceral adipose tissue (VAT) in people living with HIV-associated lipodystrophy

Joint & Muscle

Flavor:GLP-1 Craving Control Set

Oura and Function Health show that consumer health is still alive when demand is paid, frequent, and data-rich